| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 22 | 2022 | 629 | 4.690 |
Why?
|
| Head and Neck Neoplasms | 18 | 2022 | 561 | 3.160 |
Why?
|
| Mouth Neoplasms | 11 | 2022 | 206 | 2.910 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2022 | 94 | 1.890 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2020 | 231 | 1.460 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2022 | 446 | 1.360 |
Why?
|
| Papillomavirus Infections | 3 | 2022 | 194 | 1.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 87 | 0.930 |
Why?
|
| Survival Rate | 13 | 2022 | 1056 | 0.830 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 13 | 0.820 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2019 | 40 | 0.770 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2020 | 14 | 0.770 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 117 | 0.740 |
Why?
|
| Databases, Factual | 4 | 2020 | 622 | 0.670 |
Why?
|
| Immune Evasion | 1 | 2019 | 19 | 0.660 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 800 | 0.660 |
Why?
|
| Tumor Escape | 1 | 2019 | 37 | 0.650 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 179 | 0.640 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2020 | 14 | 0.630 |
Why?
|
| Laryngeal Neoplasms | 1 | 2018 | 47 | 0.630 |
Why?
|
| Tobacco Use | 1 | 2018 | 98 | 0.600 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 274 | 0.590 |
Why?
|
| Genes, p53 | 1 | 2017 | 41 | 0.570 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 61 | 0.570 |
Why?
|
| Retrospective Studies | 15 | 2022 | 7277 | 0.520 |
Why?
|
| Aged | 20 | 2022 | 14862 | 0.510 |
Why?
|
| Prognosis | 11 | 2021 | 2093 | 0.500 |
Why?
|
| Humans | 50 | 2022 | 68618 | 0.490 |
Why?
|
| Middle Aged | 23 | 2022 | 21147 | 0.460 |
Why?
|
| SEER Program | 6 | 2019 | 153 | 0.460 |
Why?
|
| Mutation | 7 | 2021 | 1213 | 0.450 |
Why?
|
| Melanoma | 3 | 2022 | 335 | 0.420 |
Why?
|
| Nasal Septum | 2 | 2009 | 16 | 0.420 |
Why?
|
| Forecasting | 1 | 2013 | 277 | 0.410 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 66 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 756 | 0.390 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 132 | 0.390 |
Why?
|
| Survival Analysis | 4 | 2021 | 714 | 0.380 |
Why?
|
| Male | 26 | 2022 | 37321 | 0.380 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2022 | 266 | 0.360 |
Why?
|
| Female | 26 | 2022 | 38074 | 0.360 |
Why?
|
| Cisplatin | 4 | 2015 | 192 | 0.360 |
Why?
|
| Nasal Cavity | 2 | 2012 | 62 | 0.340 |
Why?
|
| Turbinates | 1 | 2009 | 12 | 0.330 |
Why?
|
| Parotid Neoplasms | 2 | 2020 | 49 | 0.320 |
Why?
|
| Endostatins | 1 | 2008 | 11 | 0.320 |
Why?
|
| Aged, 80 and over | 7 | 2022 | 4848 | 0.320 |
Why?
|
| Nasal Obstruction | 1 | 2009 | 34 | 0.320 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 64 | 0.310 |
Why?
|
| Fibronectins | 1 | 2008 | 130 | 0.310 |
Why?
|
| Disease-Free Survival | 4 | 2018 | 349 | 0.310 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 1851 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 183 | 0.290 |
Why?
|
| Risk Assessment | 1 | 2013 | 2007 | 0.290 |
Why?
|
| Peptide Fragments | 1 | 2008 | 483 | 0.270 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 104 | 0.270 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1173 | 0.270 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 375 | 0.260 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 951 | 0.250 |
Why?
|
| Tongue Neoplasms | 2 | 2015 | 29 | 0.240 |
Why?
|
| Young Adult | 5 | 2022 | 5717 | 0.240 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2021 | 33 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 125 | 0.210 |
Why?
|
| Adolescent | 4 | 2022 | 8912 | 0.210 |
Why?
|
| Salvage Therapy | 1 | 2022 | 82 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2021 | 6 | 0.200 |
Why?
|
| Papillomaviridae | 1 | 2022 | 104 | 0.200 |
Why?
|
| Adult | 11 | 2022 | 21403 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 3 | 2020 | 369 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1174 | 0.190 |
Why?
|
| Cellular Senescence | 3 | 2016 | 112 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7029 | 0.180 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 8 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 18 | 0.180 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 792 | 0.180 |
Why?
|
| Incidence | 4 | 2020 | 1603 | 0.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 12 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 170 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2022 | 329 | 0.170 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2019 | 10 | 0.170 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 12 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2016 | 97 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2019 | 35 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 955 | 0.160 |
Why?
|
| Body Image | 1 | 2020 | 100 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2022 | 597 | 0.160 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 14 | 0.160 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2018 | 13 | 0.160 |
Why?
|
| Facial Nerve Diseases | 1 | 2018 | 13 | 0.160 |
Why?
|
| Facial Nerve | 1 | 2018 | 25 | 0.160 |
Why?
|
| Cohort Studies | 2 | 2021 | 2358 | 0.150 |
Why?
|
| Registries | 2 | 2018 | 733 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 1070 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 332 | 0.150 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2017 | 6 | 0.150 |
Why?
|
| Precision Medicine | 1 | 2019 | 111 | 0.150 |
Why?
|
| Carcinoma | 1 | 2019 | 215 | 0.150 |
Why?
|
| Child | 4 | 2017 | 6405 | 0.150 |
Why?
|
| Molecular Motor Proteins | 1 | 2017 | 14 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.140 |
Why?
|
| Myosin Heavy Chains | 1 | 2017 | 49 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 536 | 0.140 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 26 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2018 | 258 | 0.140 |
Why?
|
| Genomics | 2 | 2015 | 168 | 0.140 |
Why?
|
| DNA Copy Number Variations | 2 | 2014 | 27 | 0.140 |
Why?
|
| Risk Factors | 4 | 2019 | 5731 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 100 | 0.130 |
Why?
|
| Telomerase | 1 | 2016 | 85 | 0.130 |
Why?
|
| Induction Chemotherapy | 2 | 2013 | 39 | 0.130 |
Why?
|
| RNA | 1 | 2016 | 171 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 786 | 0.130 |
Why?
|
| Animals | 7 | 2022 | 20881 | 0.130 |
Why?
|
| Transfection | 1 | 2017 | 782 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 468 | 0.130 |
Why?
|
| Neck Dissection | 3 | 2021 | 55 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2003 | 16 | 0.120 |
Why?
|
| Leiomyoma | 3 | 2003 | 28 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 331 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 37 | 0.120 |
Why?
|
| Uterine Neoplasms | 3 | 2003 | 99 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 103 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 215 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 371 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 195 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2019 | 2689 | 0.110 |
Why?
|
| Texas | 1 | 2013 | 92 | 0.110 |
Why?
|
| HMGA2 Protein | 2 | 2003 | 2 | 0.110 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2013 | 14 | 0.110 |
Why?
|
| Leukoplakia, Oral | 1 | 2013 | 12 | 0.110 |
Why?
|
| Urea | 1 | 2013 | 51 | 0.110 |
Why?
|
| Transcriptome | 1 | 2015 | 164 | 0.110 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2013 | 18 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2012 | 77 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2013 | 274 | 0.110 |
Why?
|
| Thiophenes | 1 | 2013 | 76 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 271 | 0.110 |
Why?
|
| Age Distribution | 1 | 2013 | 320 | 0.110 |
Why?
|
| Frontal Sinus | 1 | 2012 | 14 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2013 | 122 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 230 | 0.110 |
Why?
|
| United States | 6 | 2021 | 7367 | 0.100 |
Why?
|
| Hyaluronan Receptors | 1 | 2012 | 142 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2013 | 193 | 0.100 |
Why?
|
| Quality of Life | 1 | 2020 | 1515 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 1667 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2012 | 239 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3259 | 0.090 |
Why?
|
| Apoptosis | 1 | 2017 | 1641 | 0.090 |
Why?
|
| DNA Damage | 3 | 2016 | 190 | 0.090 |
Why?
|
| Nose Deformities, Acquired | 1 | 2009 | 6 | 0.090 |
Why?
|
| Mice | 4 | 2022 | 8474 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2022 | 215 | 0.080 |
Why?
|
| Choanal Atresia | 1 | 2009 | 5 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 199 | 0.080 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 59 | 0.080 |
Why?
|
| Methotrexate | 1 | 2009 | 91 | 0.080 |
Why?
|
| Hypertrophy | 1 | 2009 | 89 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 236 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 247 | 0.070 |
Why?
|
| Pyrazoles | 2 | 2020 | 190 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2020 | 178 | 0.070 |
Why?
|
| Smoking | 1 | 2014 | 1452 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2008 | 384 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2015 | 294 | 0.060 |
Why?
|
| Mitosis | 2 | 2014 | 76 | 0.060 |
Why?
|
| Myometrium | 1 | 2003 | 5 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 508 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2003 | 18 | 0.060 |
Why?
|
| Leiomyomatosis | 1 | 2003 | 3 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2003 | 16 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 3705 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 69 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2324 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1753 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 51 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 40 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 213 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 15 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 108 | 0.050 |
Why?
|
| Th17 Cells | 1 | 2021 | 116 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 228 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2020 | 37 | 0.050 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2019 | 41 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 498 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 114 | 0.040 |
Why?
|
| Parotid Gland | 1 | 2018 | 33 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 383 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 130 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 2791 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2014 | 13 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2014 | 26 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 260 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 304 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 159 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 1027 | 0.030 |
Why?
|
| Gene Rearrangement | 2 | 2003 | 19 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2013 | 15 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 111 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.030 |
Why?
|
| Point Mutation | 1 | 2013 | 97 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 772 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 238 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2012 | 137 | 0.030 |
Why?
|
| Gene Expression | 1 | 2015 | 770 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 499 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2012 | 130 | 0.030 |
Why?
|
| Skull Base | 1 | 2012 | 72 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 1200 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 947 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 4655 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 235 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 434 | 0.020 |
Why?
|
| Paranasal Sinuses | 1 | 2012 | 165 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 954 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1174 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3187 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2223 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 36 | 0.020 |
Why?
|
| Cartilage | 1 | 2009 | 51 | 0.020 |
Why?
|
| Arthritis, Juvenile | 1 | 2009 | 70 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1864 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1553 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1038 | 0.020 |
Why?
|
| Rhinoplasty | 1 | 2009 | 27 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 689 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1342 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 931 | 0.020 |
Why?
|
| Culture Techniques | 1 | 2003 | 65 | 0.010 |
Why?
|
| Karyotyping | 1 | 2003 | 74 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2003 | 6 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2003 | 12 | 0.010 |
Why?
|
| Rad51 Recombinase | 1 | 2003 | 16 | 0.010 |
Why?
|
| Vascular Neoplasms | 1 | 2003 | 15 | 0.010 |
Why?
|
| Telomere | 1 | 2003 | 59 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 74 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 144 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 93 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 852 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 1664 | 0.010 |
Why?
|